Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Public ClinicalTrials.gov record NCT02623426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.
Study identification
- NCT ID
- NCT02623426
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Interventions
- Dexamethasone intravitreal implant 0.7 mg Drug
- Intravitreal Methotrexate 400 µg Drug
- Intravitreal Ranibizumab 0.5 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2017
- Primary completion
- Oct 26, 2021
- Completion
- Feb 1, 2022
- Last update posted
- Jul 9, 2023
2017 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jules Stein Eye Institute, UCLA | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Kellogg Eye Center, University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Duke Eye Center, Duke University | Durham | North Carolina | 27710 | — |
| Scheie Eye Institute, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| MidAtlanitc Retina, Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt | Nashville | Tennessee | 37232 | — |
| Retinal Consultants of Houston | Houston | Texas | 77030 | — |
| John A. Moran Eye Center, University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02623426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02623426 live on ClinicalTrials.gov.